A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1072

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

BIOLOGICAL: Ligelizumab
BIOLOGICAL: Omalizumab
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals